Minnesota 2025-2026 Regular Session

Minnesota Senate Bill SF3349 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	1.1 A bill for an act
2	2	1.2 relating to cannabis; requiring health care facilities to accommodate cannabis and
3	3	1.3 hemp products; amending Minnesota Statutes 2024, section 342.56, subdivision
4	4	1.4 2.
5	5	1.5BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
6	6	1.6 Section 1. Minnesota Statutes 2024, section 342.56, subdivision 2, is amended to read:
7	7	1.7 Subd. 2.Health care facilities.(a) Health care facilities licensed under chapter 144A;
8	8	1.8hospice providers licensed under chapter 144A; boarding care homes or supervised living
9	9	1.9facilities licensed under section 144.50; assisted living facilities under chapter 144G; facilities
10	10	1.10owned, controlled, managed, or under common control with hospitals licensed under chapter
11	11	1.11144; and other health care facilities licensed by the commissioner of health or the
12	12	1.12commissioner of human services may adopt reasonable restrictions on the use of medical
13	13	1.13cannabis flower or medical, cannabinoid products, lower-potency hemp edibles, hemp-derived
14	14	1.14consumer products, or hemp-derived topical products by a patient enrolled in the registry
15	15	1.15program who resides at or is actively receiving treatment or care at the facility. The
16	16	1.16restrictions may include a provision that the facility must not store or maintain a patient's
17	17	1.17supply of medical cannabis flower or medical cannabinoid products on behalf of the patient;
18	18	1.18that a patient store the patient's supply of medical cannabis flower or medicinal, cannabinoid
19	19	1.19products, lower-potency hemp edibles, hemp-derived consumer products, or hemp-derived
20	20	1.20topical products in a locked container accessible only to the patient, the patient's designated
21	21	1.21caregiver, or the patient's parent, legal guardian, or spouse; that the facility is not responsible
22	22	1.22for providing medical cannabis or hemp for patients; and that medical cannabis flower or
23	23	1.23medical, cannabinoid products, lower-potency hemp edibles, hemp-derived consumer
24	24	1.24products, or hemp-derived topical products are used only in a location specified by the
25	25	1Section 1.
26	26	25-04960 as introduced03/20/25 REVISOR SS/LJ
27	27	SENATE
28	28	STATE OF MINNESOTA
29	29	S.F. No. 3349NINETY-FOURTH SESSION
30	30	(SENATE AUTHORS: CLARK)
31	31	OFFICIAL STATUSD-PGDATE
32	32	Introduction and first reading04/09/2025
33	33	Referred to Commerce and Consumer Protection 2.1facility or provider. Nothing in this subdivision requires facilities and providers listed in
34	34	2.2this subdivision to adopt such restrictions.
35	35	2.3 (b) No facility or provider listed in this subdivision may unreasonably limit a patient's
36	36	2.4access to or use of medical cannabis flower or medical cannabinoid products, lower-potency
37	37	2.5hemp edibles, hemp-derived consumer products, or hemp-derived topical products to the
38	38	2.6extent that such use is authorized under sections 342.51 to 342.59, or the patient is a visiting
39	39	2.7patient authorized to use medical cannabis under the laws of their state of residence. No
40	40	2.8facility or provider listed in this subdivision may prohibit a patient access to or use of medical
41	41	2.9cannabis flower or medical cannabinoid products due solely to the fact that cannabis is a
42	42	2.10controlled substance pursuant to the federal Uniform Controlled Substances Act. If a federal
43	43	2.11regulatory agency, the United States Department of Justice, or the federal Centers for
44	44	2.12Medicare and Medicaid Services takes one of the following actions, a facility or provider
45	45	2.13may suspend compliance with this paragraph until the regulatory agency, the United States
46	46	2.14Department of Justice, or the federal Centers for Medicare and Medicaid Services notifies
47	47	2.15the facility or provider that it may resume permitting the use of medical cannabis flower or
48	48	2.16medical, cannabinoid products, lower-potency hemp edibles, hemp-derived consumer
49	49	2.17products, or hemp-derived topical products within the facility or in the provider's service
50	50	2.18setting:
51	51	2.19 (1) a federal regulatory agency or the United States Department of Justice initiates
52	52	2.20enforcement action against a facility or provider related to the facility's compliance with
53	53	2.21the medical cannabis program; or
54	54	2.22 (2) a federal regulatory agency, the United States Department of Justice, or the federal
55	55	2.23Centers for Medicare and Medicaid Services issues a rule or otherwise provides notification
56	56	2.24to the facility or provider that expressly prohibits the use of medical cannabis in health care
57	57	2.25facilities or otherwise prohibits compliance with the medical cannabis program.
58	58	2.26 (c) An employee or agent of a facility or provider listed in this subdivision or a person
59	59	2.27licensed under chapter 144E is not violating this chapter or chapter 152 for the possession
60	60	2.28of medical cannabis flower or medical cannabinoid products while carrying out employment
61	61	2.29duties, including providing or supervising care to a patient enrolled in the registry program,
62	62	2.30or distribution of medical cannabis flower or medical cannabinoid products to a patient
63	63	2.31enrolled in the registry program who resides at or is actively receiving treatment or care at
64	64	2.32the facility or from the provider with which the employee or agent is affiliated.
65	65	2.33 (d) Nothing in this subdivision is intended to require a facility covered by this subdivision
66	66	2.34to permit violations of sections 144.411 to 144.417.
67	67	2Section 1.
68	68	25-04960 as introduced03/20/25 REVISOR SS/LJ